| Literature DB >> 27069710 |
Chris Richard Kenyon1, Achilleas Tsoumanis2, Kara Osbak3.
Abstract
Background. Syphilis is curable but Herpes Simplex Virus-2 (HSV-2) is not. As a result, the prevalence of syphilis but not HSV-2 may be influenced by the efficacy of national STI screening and treatment capacity. If the prevalence of syphilis and HSV-2 is found to be correlated, then this makes it more likely that something other than differential STI treatment is responsible for variations in the prevalence of both HSV-2 and syphilis. Methods. Simple linear regression was used to evaluate the relationship between national antenatal syphilis prevalence and HSV-2 prevalence in women in two time periods: 1990-1999 and 2008. Adjustments were performed for the laboratory syphilis testing algorithm used and the prevalence of circumcision. Results. The prevalence of syphilis was positively correlated with that of HSV-2 for both time periods (adjusted correlations, 20-24-year-olds: 1990-99: R (2) = 0.54, P < 0.001; 2008: R (2) = 0.41, P < 0.001 and 40-44-year-olds: 1990-99: R (2) = 0.42, P < 0.001; 2008: R (2) = 0.49, P < 0.001). Conclusion. The prevalence of syphilis and HSV-2 is positively correlated. This could be due to a common set of risk factors underpinning both STIs.Entities:
Year: 2016 PMID: 27069710 PMCID: PMC4812442 DOI: 10.1155/2016/5959032
Source DB: PubMed Journal: J Sex Transm Dis ISSN: 2090-7958
Figure 1Conceptual framework illustrating the relationship between syphilis, HIV, and HSV-2 prevalence and four underlying risk factors. Syphilis prevalence is directly and HIV prevalence is indirectly influenced by STI treatment efficacy. HSV-2 is not influenced by STI treatment efficacy.
Figure 2Association between unadjusted antenatal syphilis prevalence and national HSV-2 prevalence and 20–24-year-old women (a) and 40–44-year-old women (b), all data from 1990–1999.
Figure 3The antenatal prevalence of syphilis by country in 1990–1999 (a) and 2008 (b), unadjusted for testing strategy, the 1990–1999 prevalence of HSV-2 by country in 20–24-year-old women (c) and 40–44-year-old women (d), and the peak prevalence of HIV by country (e).